SELLAS Life Sciences Group (SLS) stock, explained like you're 5

Is SELLAS Life Sciences Group a small, medium or large cap company?

No. SELLAS Life Sciences Group is a mid cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 2.4 billion dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How SELLAS Life Sciences Group makes money

• Selling medicines, medical devices or healthcare services.
• Insurance premiums or hospital and clinic fees.
• Research and licensing deals.

What moves SLS stock

• Results from clinical trials and approvals from regulators.
• Drug prices, insurance rules and government policy.
• Patents running out and new competing treatments.

In the news lately

• SLS Stock July Rout Deepens: ‘Pharma Bro’ Martin Shkreli Questions Timing Of AML Trial, Says Data May Wait Until Christmas (Stocktwits)
• SLS Stock Slides As Pomerantz Probes Trial Disclosure (Timothy Sykes)
• SLS Jan 2029 22.000 call (SLS290119C00022000) stock price, news, quote and history (Yahoo Finance UK)
• SLS Stock Jumps Premarket: CEO Says GPS AML Data Has ‘Very Good Chance’ To Beat Earlier Survival Outcomes (Stocktwits)
• SLS Stock Rises Overnight: Retail Traders Call New AML Survival Data 'Huge' Ahead Of CEO’s Fox Appearance (Stocktwits)

Key terms to know before you follow SLS

• Market cap
• P/E ratio
• EPS (earnings per share)
• Earnings report
• Volatility